Cyrus K. MirsaidiPresident and CEO
Mr. Mirsaidi brings both practical and strategic senior management experience for young start-ups to fortune 100 companies, with proven track record from FDA regulated clinical diagnostics to high throughput compound library synthesis and purification, and from pre-clinical drug development, to clinical programs for targeted therapeutics in translational oncology. He held several senior level management positions in his ten-year career at Nichols Institute Diagnostics (a division of Quest Diagnostics), where he was responsible for global launch of FDA regulated, clinical diagnostic IVD tests and automated platforms. As general manager and executive director at Ontogen, a small molecule discovery company, he managed operations of a subsidiary focused on high throughput synthesis and purification of novel chemical compounds. Mr. Mirsaidi served as Vice President at AltheaDx, a spin-out from Althea Technologies, a San Diego biologics GMP manufacturing company, and most recently served as CEO and founder of Molecular Response, LLC, a CRO focused on translational oncology.
Ian WisenbergChief Financial Officer
Ian Wisenberg has more than 30 years’ experience in international business with an emphasis in finance, capital formation and business development.
He is Chief Financial Officer for BioDuro and Formex as well as a principle and Chief Business Officer for the Biotech Investment Group.
Prior to joining BioDuro and Formex as full-time CFO, Ian ran a very successful consulting practice, BioGlobal Consulting Group which had an extensive client list with Biotech and Pharma companies both in the USA and abroad.
He was also co-founder and Managing Director of ChinaBio Capital Partners where he served as Chief Business Officer working with key executives and investors in the United States and Europe exploring investment and strategic opportunities in China.
Ian previously served as the Senior Vice President of Business Development and CFO of BIOCOM – the world’s largest regional life science trade organization.
Bringing a broad portfolio of expertise, Ian has a solid track record in Finance and Administration. His Capital Development initiatives are aimed at establishing strategic financial partnerships with local, national and international financing institutions. He was also responsible for the establishment of the first VC incubator in San Diego. Of equal significance is his ability to foster international relations with government agencies and private institutions.
Mr. Wisenberg is also past treasurer for the San Diego Venture Group.
Prior to BIOCOM, he was Vice President of finance and administration, as well as interim President, Secretary and treasurer of Aerocast, Inc., a secured broadband media streaming company.
Born in Cape Town, South Africa, Mr. Wisenberg holds a Bachelor of Commerce Degree in accounting from Cape Town University and practiced as a Certified Public Accountant (now inactive).
J. Blair WestChief Scientific Officer
Blair West joined Formex as CSO in 2013, with over 25 years of industry experience.
Previously Dr. West was VP of Pharmaceutical Operations from 2010-2013 at PharmaForm.
Dr. West also served as Senior VP of Technical Affairs, Formulations and CTM Manufacturing at AzoPharma, a CRO, for 5 years. Prior to that, he was Director of Pharmaceutical Chemistry at Bend Research between 1988 and 2004, where he focused on technology development in the areas of solubilization, chemical and physical stabilization, drug discovery and drug delivery for various drug product dosage forms.
Dr. West holds an undergraduate degree in Biochemistry from Harvard, and received his PhD in Bio-organic Chemistry from Texas A&M. His expertise includes peptide and synthetic organic chemistry, applied bio-organic chemisty, bioprocessing, development of drug delivery technologies, drug absorption technologies, formulation development, solubilization, bioavailability enhancement, and controlled release technology development.
Greg WeilersbacherDirector of Quality Assurance and Quality Control
Greg Weilersbacher has over 20 years of pharmaceutical industry experience with focused expertise in Quality Assurance , Facility Validation, GMP manufacturing, , and laboratory operations.
From 2010 to 2014 he was a pharmaceutical industry consultant serving start-ups through major pharma. He has held the role of Associate Director of QA/QC at La Jolla Biologics (2011 to 2014), Manager and Director of Quality Assurance positions at Pharmatek laboratories (2002 to 2010), Manager of Quality at Corvas International (2001 to 2002), QA Associate at Magellan Laboratories (1999 to 2001), and Analytical Chemist at Amylin Pharmaceuticals (1994 to 1998). Greg’s interests include building and developing small pharmaceutical companies and GMP facility design and validation.
Formex LLC is a leading contract development and manufacturing organization focusing on oral and topical dosage forms.
Formex specializes in bioavailability enhancement and controlled release technologies, such as hot melt extrusion and spray drying.
Formex provides pre-formulation, formulation development, analytical method development, analytical testing, pre-clinical manufacturing, cGMP clinical trial manufacturing for Phase 0-IIb & small scale cytotoxic and high potent compound manufacturing.
Formex is a wholly-owned subsidiary of the Biotech Investment Group (BIG). BIG, founded in 2006, is a provider of growth equity capital to emerging healthcare services companies. BIG’s mission is to partner with outstanding entrepreneurs to build long-lasting companies and deliver services which address significant unmet healthcare needs.